Currently, Fe-based catalysts show excellent catalytic performance in the hydrogenation of CO 2 to produce light olefins. Despite numerous studies, the identification of the role of catalytically active components over Fe-based catalysts for CO 2 hydrogenation is not quite clear. In this work, a series of ZrO 2supported cobalt-doped Fe-based catalysts were fabricated by a microliquid film reactor-assisted coprecipitation method. It was demonstrated that appropriately strong interactions between Fecontaining species and the ZrO 2 support in catalyst precursors could facilitate the generation of a defective FeO x component upon reduction treatment and inhibit the carburization of metallic iron during the reaction. Among all Fe-based catalysts, the catalyst bearing a (Co + Fe)/ZrO 2 mass ratio of 3:7 and a Co/Fe molar ratio of 1:9 achieved a highest light olefins selectivity of about 38% at 49% CO 2 conversion under reaction conditions (i.e., 320 °C, 2.0 MPa, and 4800 mL•g cat −1 •h −1 ), along with a high Fe time yield to light olefins of 9.2 μmol COd 2 •g Fe −1•s −1 and a low CO selectivity of 4.7%. Comprehensive structural characterization and catalytic CO 2 hydrogenation experiments clarified that the surface-dominant defect-rich FeO x component as catalytically active species substantially played a crucial role in governing the hydrogenation of CO 2 , mainly owing to their enhanced adsorption and binding ability for CO 2 and the CO intermediate. This study offers a new strategy to design Fe-based catalysts and provides deep insight into the role of iron oxide species for CO 2 hydrogenation to produce light olefins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.